Director of the DMD Program at UMass Chan Medical School.
In this discussion, Dr Brenda Wong explores how families can be supported by advocacy organizations after a Duchenne muscular dystrophy diagnosis. She elaborates on how care needs evolve across the lifespan, and how advocacy organizations can help guide multidisciplinary care, treatment decisions, care transitions, and participation in cutting edge DMD research.
Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]
A duo of experts from CureDuchenne discussed how the inclusion of Duchenne muscular dystrophy on the Recommended Uniform Screening Panel can enable earlier diagnosis and inform decision-making in a rapidly evolving therapeutic landscape. [WATCH TIME: 7 minutes]
The director of the DMD Program at UMass Chan Medical School shared her experience at the 2025 CureDuchenne FUTURES National Conference, held May 22-25, in San Antonio, Texas. [WATCH TIME: 5 minutes]
February 17th 2026
